Found it in Investor presentation dated 11th Dec 2023.
Long term development program repurposing existing oral drugs to intransal delivery.
Additional ED products increasing range by dosage and using other PDE5 inhibitors.
Pulmonary Arterial Hypertension- a disorder characterised by high blood pressure in the arteries of the lungs.
Scleroderma-Immune disorder attacking healthy tissues,triggering the narrowing of blood vessels.
Osteoperosis-thin,weak,fragile bones prone to fracture.
Based on the above I consider the current share price is very reasonable.Not investment advice DYOR.
Revenue - what does it look like?, page-62
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LTP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.25 |
Change
-0.010(0.79%) |
Mkt cap ! $105.9M | |||
| Open | High | Low | Value | Volume |
| $1.26 | $1.33 | $1.23 | $617.7K | 487.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 11277 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.28 | 1327 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| LTP (ASX) Chart |